Clinical Impact of New Data From CROI 2021

March 6-10, 2021; Virtual
In this downloadable slideset, CCO’s expert faculty members summarize key studies from this important annual conference, including new data on the following hot topics: HIV PrEP strategies; ART in pregnancy, the postpartum period, children and adolescents; racial disparities in COVID-19 outcomes among PWH; HIV and coinfections/comorbidities; and current and investigational ART.
Princy N. Kumar, MD, FIDSA, MACP
Daniel R. Kuritzkes, MD
Chloe Orkin Photo
Chloe Orkin, MBChB, FRCP, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 954 KB
Released: March 30, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

CCO commentary by Professor Don Smith on CROI 2021 data on ARV-associated weight gain and long-acting injectable ART

person default Don Smith, MD Released: April 20, 2021

Drs Monica Gandhi and Joseph Eron discuss next-line ART options for a heavily treatment-experienced patient with multiclass resistance .

Joseph J. Eron, Jr., MD Monica Gandhi, MD, MPH Physicians: maximum of 0.5 AMA PRA Category 1 Credits Pharmacists: 0.5 contact hours (0.05 CEUs) Released: April 19, 2021 Expired: April 18, 2022

Clinical Care Options (CCO) commentary by Dr Zhao Yan on data presented at CROI 2021 on the impact of the COVID-19 pandemic on HIV treatment

Dr. Zhao Yan Released: April 19, 2021

Download CCO slides reviewing data and guidelines on next-line ART for heavily-treatment experienced patients with HIV and multiclass drug resistance

Joseph J. Eron, Jr., MD Monica Gandhi, MD, MPH Released: April 19, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue